Sarah Bennett
The AstraZeneca COVID-19 vaccine has been found to offer minimal protection against the South African variant of the virus, also known as the B.1.351 variant. A phase 1b-2 clinical trial found that two doses of the vaccine were only 10.4% effective against mild-to-moderate infections caused by the South African variant. This has raised concerns as the South African variant shares similar mutations with other variants, potentially exposing vaccinated individuals to multiple strains. In response, efforts are being made to accelerate the development of second-generation vaccines that can provide greater protection against the South African variant and other emerging strains. While the AstraZeneca vaccine may not be fully effective against the South African variant, it is still recommended for those who have the opportunity to receive it as it can offer some level of protection against hospitalization and death.
| Characteristics | Values |
|---|---|
| Efficacy against mild-to-moderate COVID-19 caused by the B.1.351 South Africa variant | 10.4% |
| Number of trial participants | 750 vaccine recipients |
| Number of COVID-19 cases | 42 |
| Number of cases caused by the B.1.351 South Africa variant | 39 (92.9%) |
| Number of hospitalizations or deaths | 0 |
| Median age of participants | 30 years old |
| Countries relying on the AstraZeneca vaccine | 130 |
| Date of study publication | April 1, 2021 |
Explore related products
What You'll Learn
- AstraZeneca vaccine has minimal efficacy against mild-moderate illness
- South African variant shares similar mutations with other variants
- AstraZeneca vaccine may protect against severe illness
- South African variant is spreading fast globally
- Second-generation vaccines are needed to protect against variants
AstraZeneca vaccine has minimal efficacy against mild-moderate illness
The AstraZeneca vaccine has shown minimal efficacy in preventing mild-to-moderate illness caused by the South African variant of COVID-19, also known as the B.1.351 variant. A phase 1b-2 clinical trial published in the New England Journal of Medicine found that the vaccine had only 10.4% efficacy against mild-to-moderate infections caused by this variant. This is a concerning development as the South African variant shares similar mutations with other variants, leaving those vaccinated with the AstraZeneca vaccine potentially vulnerable to multiple strains of the virus.
The trial evaluated the safety and efficacy of the AstraZeneca vaccine in 2,026 HIV-negative adults aged 18 to 64, with a median age of 30. Out of the 750 vaccine recipients in the trial, 19 (2.5%) developed mild to moderate COVID-19 more than 14 days after the second dose, compared to 23 out of 717 (3.2%) in the placebo group. Of the 42 COVID-19 cases, 39 (92.9%) were caused by the B.1.351 variant, demonstrating the reduced effectiveness of the AstraZeneca vaccine against this particular strain.
While the AstraZeneca vaccine may not provide strong protection against mild-to-moderate illness caused by the South African variant, it is important to note that the trial did not report any cases of hospitalization or death among the participants. The relatively young median age of the participants likely influenced the lack of severe COVID-19 cases. Scientists believe that the vaccine may still protect against more severe cases, and further studies are needed to confirm this.
In response to these findings, South Africa halted the rollout of the AstraZeneca vaccine in February 2021. This setback prompted the development of a modified version of the vaccine to better combat the South African variant. While the efficacy against mild-to-moderate illness may be minimal, the AstraZeneca vaccine still offers some level of protection against the virus, and it is recommended that those with the opportunity to receive the current vaccine should do so to protect against the risk of hospitalization and death.
Free Vaccines at CVS: What's the Catch?
You may want to see also
Explore related products
South African variant shares similar mutations with other variants
The AstraZeneca vaccine has been found to offer only minimal protection against mild-to-moderate infections caused by the B.1.351 South African variant. According to a clinical trial, the vaccine was only 10.4% effective against the variant. This is a significant cause for concern as the South African variant shares similar mutations with other variants, leaving those vaccinated with the AstraZeneca vaccine potentially vulnerable to multiple strains of the virus.
The South African variant shares the E484K and K417N mutations with the Brazilian variant, and both variants also feature the N501Y mutation in the spike protein, which increases the virus's ability to access human cells for replication. This mutation has also been found in the UK variant. The South African variant's rapid spread may be attributed to this mutation.
The South African variant also shares similarities with the Omicron variant, which was first discovered in samples from Botswana and South Africa in November 2021. The Omicron variant is marked by at least 30 amino acid substitutions, three small deletions, and one small insertion. These mutations have resulted in a reduction in vaccine effectiveness, higher transmissibility, and an increased risk of reinfection and immune escape.
The South African variant also shares a common mutation with other variants that indicates a common ancestry. This mutation is separate from the characteristic trio of mutations that link other variants worldwide, highlighting the adaptability of SARS-CoV-2 to local conditions.
Rabies Vaccine: A Historical Overview
You may want to see also
Explore related products
AstraZeneca vaccine may protect against severe illness
A phase 1b-2 clinical trial published in the New England Journal of Medicine found that two doses of the AstraZeneca Covid-19 vaccine were only 10.4% effective against mild-to-moderate infections caused by the B.1.351 South Africa variant. This is concerning as the South African variant shares mutations with other variants, potentially exposing vaccinated individuals. However, it's important to note that no hospitalizations or deaths were observed in the study, and the young median age of participants likely influenced this outcome.
While the AstraZeneca vaccine may not offer strong protection against mild-to-moderate illness from the South African variant, it could still protect against severe illness. Scientists in South Africa believe that the vaccine might protect against more severe cases based on immune responses detected in blood samples from vaccinated individuals. Professor Shabir Madhi, who led the trial, stated that while the results are a reality check, he believes protection against severe illness is biologically plausible.
Furthermore, the University of Oxford, which co-developed the vaccine, is working on a booster jab to provide additional protection against the South African variant if necessary. This underscores the ongoing efforts to ensure vaccine efficacy against emerging variants.
In the meantime, the current AstraZeneca vaccine can still protect against the risk of hospitalization and death, especially in countries relying on it to vaccinate their populations. As Dr. Anthony Fauci stated, even with reduced efficacy, vaccines can remain within a protective range. While we await updated vaccines, accepting the current AstraZeneca vaccine can help protect against severe outcomes.
The TDAP Vaccine: Late 70's Children and Their Immunization
You may want to see also
Explore related products
South African variant is spreading fast globally
The South African variant of Covid-19 has been spreading fast globally. The Omicron variant, first detected in South Africa in November 2021, has since spread across the world, with four distinct lineages (BA.1, BA.2, BA.4, and BA.5) dominating SARS-CoV-2 diversity. South Africa has experienced multiple waves of SARS-CoV-2 infections since the start of the pandemic, with two of the five variants of concern (Beta and Omicron) first detected in the region.
The rapid evolution and global spread of SARS-CoV-2 variants from South Africa highlight the need for ongoing genomic surveillance and a comprehensive regional surveillance network. The early transmission dynamics and geographic origins of these variants are crucial to understanding their success and dissemination. South Africa's role in the emergence of the Beta VOC and potentially dominant Omicron lineages underscores the importance of analyzing variant dynamics in the country.
The spread of the South African variant has been facilitated by its highly contagious nature and the mixing of populations. By June 2021, the variant was detected in India and 21 other countries across Asia, Europe, the US, and Australia. As of February 2021, the South African strain was reported to be in 30 countries and spreading quickly. The dynamic tracking of SARS-CoV-2 mutants during the global pandemic revealed an increase in mutation frequency and the emergence of new variants, including the South African lineage.
The rapid spread of the South African variant has had significant implications for the development and effectiveness of vaccines. Studies have shown that the AstraZeneca vaccine offers limited protection against mild to moderate infections caused by the South African variant, with an efficacy rate of only around 10%. This has prompted countries relying on AstraZeneca to vaccinate their populations to reconsider their strategies and accelerate the development of second-generation vaccines that specifically target the South African variant.
US Troops and the Ebola Vaccine: Who Got It?
You may want to see also
Explore related products
Second-generation vaccines are needed to protect against variants
The AstraZeneca vaccine has been found to offer only limited protection against the South African COVID-19 variant, B.1.351. A clinical trial found that two doses of the vaccine were only 10.4% effective against mild-to-moderate infections caused by the variant. This is a significant cause for concern, as the South African variant shares mutations with several other variants, potentially exposing vaccinated individuals to multiple strains.
The South African variant is spreading fast and is now present in 30 countries. This is an urgent issue, as no one will be completely protected from COVID-19 until everyone is. While the AstraZeneca vaccine does offer some protection against severe illness and death, the development of second-generation vaccines is crucial to preventing another wave of infections and returning to normality.
To achieve this, governments and vaccine developers must work together to leverage public-private partnerships and advance new technologies. This includes investing in flexible, rapid-response technologies, such as mRNA vaccines, which can be reprogrammed for any pathogen once its genetic sequence is known. Indeed, the speed at which mRNA vaccines can be developed was crucial in the rapid deployment of COVID-19 vaccines.
While updated vaccines are being developed, it is important for individuals to continue accepting the current AstraZeneca vaccine to protect themselves against severe illness and death. However, the development and distribution of second-generation vaccines must be accelerated to address the ongoing threat of new variants.
How Conjugate Vaccines Stimulate T-Cell Defense
You may want to see also
Frequently asked questions
No, the AstraZeneca vaccine does not protect against the South African variant.
The South African variant, also known as B.1.351, is a variant of SARS-CoV-2 which contains several mutations that cut the ability of antibodies to neutralise the virus.
No, it does not mean that. While the AstraZeneca vaccine does not protect against the South African variant, it is still effective against other variants of COVID-19.
Second-generation vaccines that specifically target the South African variant are currently in development. In the meantime, the current AstraZeneca vaccine can still protect against the risk of hospitalization and death.
